Evidence map›Paper›PMID 42907899›Full record

ArticleJournal of nanobiotechnology2026

Identification of the miR-210-3p-EFNA3-YAP axis and its targeted modulation via biomimetic supramolecular nanoparticles to promote ischemic flap survival.

Jie Xu, Xiuxiu Zhuang, Zichang Wu, Fuyi Yan, Deen Shi, Fan Ye, Ruihua Ding, Qi Gao, Qimin Yao, Yiying Liu and 10 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jie Xu *Department of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China.
Xiuxiu Zhuang *Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Zichang WuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Fuyi YanOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Deen ShiDepartment of Radiology, Ruian Hospital Affiliated to Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Fan YeOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Ruihua DingOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Qi GaoOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Qimin YaoOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Yiying LiuThe Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Xiaoyu DongDepartment of Wound healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Fan ZhangOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Binbiao LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Xiangwei XuDepartment of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China.
Hongfei TongDepartment of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China.
Yanzhi YaoDepartment of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China.
Wenbing JiangThe Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. jiangwb919@wmu.edu.cn.
Jian XiaoDepartment of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China. xjian@wmu.edu.cn.
Zhenglin LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. chmlzh@wmu.edu.cn.
Wei ChenDepartment of Orthopaedics, Yongkang First People's Hospital of Wenzhou Medical University, Jinhua, 321300, Zhejiang, China. m13566758233@163.com.

Funding

National Natural Science Foundation of China under Grant 82202466the Start-up Funding of Wenzhou Medical University under Grant 89223001
6 · The paper itself

Abstract

Ischemic skin flaps are highly susceptible to distal necrosis because of insufficient perfusion, oxidative stress, and dysregulated cell death. Here, we investigated the role of Hippo/YAP signaling in ischemic flap survival and identified its upstream regulatory mechanism. Hippo pathway inactivation, characterized by reduced MST1/2 and LATS1/2 phosphorylation and enhanced YAP nuclear localization, was preferentially associated with viable flap regions. Mechanistically, ischemia-induced HIF-1α upregulated miR-210-3p, which suppressed ephrin-A3 (EFNA3), weakened the EFNA3-YAP interaction, and promoted YAP nuclear translocation. Re-expression of EFNA3 partially reversed miR-210-3p-induced YAP activation and cytoprotection, confirming its functional involvement. Mechanistically, ischemia-induced HIF-1α increased miR-210-3p expression, which suppressed EFNA3 and facilitated YAP nuclear localization. EFNA3 re-expression partially reversed miR-210-3p-induced YAP activation, supporting its functional involvement. MiR-210-3p treatment was further associated with reduced oxidative injury, lipid peroxidation, mitochondrial dysfunction, and ferroptosis-related molecular alterations, together with improved perfusion and flap survival. In vivo, miR-210-3p improved local perfusion and flap survival. We further developed a virus-inspired biomimetic nanoparticle for miR-210-3p delivery, which achieved protective effects comparable to AAV-mediated delivery in vitro and in vivo. These findings identify the miR-210-3p-EFNA3-YAP axis as an important regulator of ischemic tissue adaptation and provide a non-viral miRNA delivery strategy for ischemic flap repair.

Indexed as

Adaptor Proteins, Signal TransducingBiomimetic MaterialsEphrin-A3IschemiaMicroRNAsNanoparticlesAnimalsCell Cycle ProteinsMaleMiceOxidative StressSignal TransductionYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsEphrin-A3MicroRNAsMIRN210 microRNA, humanMIRN210 microRNA, mouseYap1 protein, mouseYAP-Signaling ProteinsHippo signaling pathwayIschemic flapmiRNAVirus-Inspired nanoparticle

Identifiers

PMID42907899
PMCPMC13689359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.